Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Rating) was the target of a large decrease in short interest in September. As of September 15th, there was short interest totalling 5,900,000 shares, a decrease of 16.7% from the August 31st total of 7,080,000 shares. Based on an average daily trading volume, of 10,560,000 shares, the short-interest ratio is currently 0.6 days.

Institutional Investors Weigh In On Kiora Pharmaceuticals

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Renaissance Technologies LLC bought a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Rating) during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 93,619 shares of the company's stock, valued at approximately $58,000. Renaissance Technologies LLC owned about 0.74% of Kiora Pharmaceuticals as of its most recent filing with the SEC. 30.61% of the stock is owned by institutional investors and hedge funds.

Kiora Pharmaceuticals Stock Performance

Shares of KPRX traded down $0.57 on Friday, reaching $6.15. The stock had a trading volume of 258,453 shares, compared to its average volume of 317,538. The firm has a 50-day moving average of $12.25 and a 200 day moving average of $16.61. Kiora Pharmaceuticals has a twelve month low of $4.86 and a twelve month high of $92.00.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on KPRX shares. HC Wainwright cut their target price on Kiora Pharmaceuticals from $120.00 to $100.00 and set a "buy" rating for the company in a research note on Monday, July 11th. LADENBURG THALM/SH SH initiated coverage on Kiora Pharmaceuticals in a report on Thursday, August 25th. They issued a "buy" rating on the stock. Finally, Maxim Group cut Kiora Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, August 15th.

About Kiora Pharmaceuticals

(Get Rating)

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.

Featured Stories

• Get a free copy of the StockNews.com research report on Kiora Pharmaceuticals (KPRX)
• EV Battery Maker Freyr Set For Major Global Expansion
• MarketBeat: Week in Review 9/26 – 9/30
• This Is A Memorable Time To Buy Into Micron Technology
• Declining Profits Challenge the CarMax Value Proposition
• How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?

Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.